The Female Health Company's Distributor, Sekunjalo Investments Corporation (Pty)
Ltd., Awarded Contract for up to 11 Million FC2 Female Condoms in the Republic of
South Africa
CHICAGO, Sep. 19, 2011 /PRNewswire via COMTEX/ -- The Female Health Company
(nasdaq-cm:FHCO) today announced that its exclusive distributor in the Republic
of South Africa (RSA), Sekunjalo Investments Corporation (PTY) Ltd., was awarded
a contract to supply the Ministry of Health (MOH) up to 11 million FC2 Female
Condoms. The contract is valid through August 31, 2012. The tender quantity of 11
million units is a significant increase from the RSA's last tender (4 million
units), evidencing the country's growing demand for female condoms. Units
supplied during the contract term can be increased over the specified quantity at
the purchasers' request.
O.B. Parrish, Chairman and C.E.O. of The Female Health Company, noted that "the
Company is delighted at RSA's decision to continue to supply our high-quality,
effective product that provides women with options to control their sexual
health, particularly HIV/AIDS prevention".
The FC2 Female Condom has been approved by the FDA as a Class III medical device
and has been cleared by the World Health Organization for purchase by U. N.
Agencies.
About The Female Health Company
The Female Health Company (FHC), based in Chicago, Illinois, manufactures and
markets the FC2 Female Condom? (FC2), which is available in the U.S. and about
100 other countries around the world. The Company owns certain worldwide rights
to the FC2 Female Condom?, including patents that have been issued in the U.S.,
Europe, Canada, Australia, South Africa, Japan, China, Spain, Mexico, Greece and
Turkey and are pending in various countries. The FC2 Female Condom? is the only
available FDA-approved product controlled by a woman that offers dual protection
against sexually transmitted diseases, including HIV/AIDS, and unintended
pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by
U.N. agencies.
About Sekunjalo Investments Corporation (PTY) Ltd.
Sekunjalo Investments Corporation Pty Ltd was established fourteen years ago for
the express purpose of supplying the South African National Dept. of Health with
male condoms on government tender. Sekunjalo has been FHC's chosen partner in the
Republic of South Africa for seven years, successfully supplying Female Condoms
to hundreds of government clinics across the provinces on tender. The Sekunjalo
partnership also owns and operates Barrs Pharmaceuticals, a GMP-approved
pharmaceutical factory located in Cape Town, from which it supplies many
medicinal products to governments in Southern Africa, also through tender
processes.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this release which are not historical fact are "forward-looking
statements" as that term is defined in the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this release relate to the timing and
size of shipments under the RSA's contract. These statements are based upon the
Company's current plans and strategies, and reflect the Company's current
assessment of the risks and uncertainties related to its business, and are made
as of the date of this release. The Company assumes no obligation to update any
forward-looking statements contained in this release as a result of new
information or future events, developments or circumstances. Such forward-looking
statements are inherently subject to known and unknown risks and uncertainties.
The Company's actual results and future developments could differ materially from
the results or developments expressed in, or implied by, these forward-looking
statements. Factors that may cause actual results to differ materially from those
contemplated by such forward-looking statements include, but are not limited to,
the following: product demand and market acceptance; competition in the Company's
markets and the risk of new competitors and new competitive product
introductions; the Company's reliance on its international partners in the
consumer sector and on the level of spending on the female condom by country
governments, global donors and other public health organizations in the global
public sector; the economic and business environment and the impact of government
pressures; risks involved in doing business on an international level, including
currency risks, regulatory requirements, political risks, export restrictions and
other trade barriers; the Company's production capacity, efficiency and supply
constraints; and other risks detailed in the Company's press releases,
shareholder communications and Securities and Exchange Commission filings,
including the Company's Form 10-K for the fiscal year ended September 30, 2010.
Actual events affecting the Company and the impact of such events on the
Company's operations may vary from those currently anticipated.
For more information about the Female Health Company visit the Company's website
at femalehealth.com and femalecondom.org. If you would like
to be added to the Company's e-mail alert list, please send an e-mail to
FHCInvestor@femalehealthcompany.com. |
